Recordati’s Post

Longitude portfolio company Alpha-9 Oncology and NorthStar Medical Radioisotopes, LLC recently announced a long-term strategic supply agreement for NorthStar to provide Alpha-9 with its non-carrier added (n.c.a.) Ac-225 for use in its targeted radiopharmaceutical programs for treatment of solid and liquid tumors. "The Alpha-9 team is well positioned to progress multiple targets into the clinic," said Alpha-9 Oncology CEO David Hirsch, MD, Ph.D. "Robust supply of high-quality Ac-225 will help us advance a new generation of highly effective radiopharmaceuticals with improved tumor uptake and limited off-target exposure. We look forward to working with NorthStar and bringing our molecules to patients." Learn more about the new agreement: https://lnkd.in/enZfyRZP #radiopharmaceuticals #biotech #biotechnology

Another attractive molecule to watch at AACR 2024 (April 5-10, San Diego) is EpimAb Biotherapeutics, Inc.’s EMB-07. This ROR1/CD3 bispecific is currently undergoing phase 1 clinical trial and will be featured in the Late-Breaking Research Poster Presentation. EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform led them a deal with Almirall for up to $210M last year. While ROR1 has been a prominent target in recent years, interest waned following the clinical trial failure of Onceternal's zilovertamab. Several ROR1 targeting ADCs and CAR-T therapies are still in development. EpimAb's EMB-07 stands out as one of the two ROR1 targeting T cell engagers in clinical trials. The other, NovalGen's NVG-111, is also in phase 1, with early data suggesting promising efficacy. Anticipation is high for the results of EMB-07, especially given its dual targeting of both liquid and solid tumors. Check link for more detail: https://www.aacr.org Additionally, the 2024 Annual Conference of our society, featuring numerous novel modalities of biologics, will convene in Cambridge, MA, USA on Saturday, May 11, 2024. Registration for the conference is now open via the following link. https://lnkd.in/ecmFPA4v #antibodydiscovery #antibodydrugconjugates#oncology #annualmeeting #annualconference #carttherapy

Randomized controlled clinical trials are regulatory agencies’ preferred approach for registrational studies in new drug and biologics development. However, there are circumstances in oncology when a single-arm trial may be more appropriate. Check the Citeline summary on the key Veristat presentation on the topic > https://bit.ly/45GAIwv #singlearmtrial #oncology

Ratio’s CDO Jacob Hesterman, Ph.D., recently co-authored a paper in the Journal of Clinical Oncology titled, “How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.”      The article addresses several issues regarding #radiopharmaceutical therapy (RPT) trials in oncology, including the designation of absorbed dose (AD) constraints by the FDA and the dearth of reporting on patient tissue ADs and toxicities.     At Ratio, our commitment to radiopharmaceutical therapies extends beyond the development of our own technology platforms. We’re proud to contribute to improving industry-wide practices for radiopharmaceutical clinical trials. Faster, more efficient trials mean these potentially life-changing treatment reach patients in need sooner.     Read the full article: https://lnkd.in/enH8Rdk6     #radiopharmaceuticals #radiotherapeutics #oncology 

The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB

This weekend the DKFZ German Cancer Research Center was hosting the NCT 2nd National Conference Patients as Research Partners - entirely organized by #patientexperts. It was an honor to participate and discuss with Bärbel Söhlke, Rainer Göbel, Richard Schlenk, Julia Ritzerfeld and Michael Zaiac about opportunities and challenges in #clinicaltrials in 🇩🇪. We need to act now 💪to ➡️leverage the NCT network to be faster especially with contract negotiations ➡️leave silos and integrate practice-based oncologists ➡️secure patients access to 🎯💊drugs by finding new re-embursement models for precision oncology drugs because ➡️drugs withdrawn (#Amivantamab The Janssen Pharmaceutical Companies of Johnson & Johnson), (#Capmatinib Novartis) or not at all launched in 🇩🇪 (#Opdualag Bristol Myers Squibb) cost lifetime of patients

Absolutely incredible to see the harmony developing between two of my previous co-op employers, Roche and Recursion (Cyclica at the time). I've been very fortunate to see the digital revolution in the biotech sector firsthand, and am really looking forward to what is to come. As companies like these aim to scale up their efforts, identifying new opportunities for #partnerships and #collaborations, bringing together each company's strengths, is all the more critical. This partnership will not only push the known boundaries of software-facilitated drug discovery, but set a standard for new medicines to be discovered, validated, and ultimately delivered to patients faster. #techbio #drugdiscovery

EFPIA's article discusses the potential of Precision Oncology (PO) in Europe beyond 2025. 🌍 1️⃣ PO aims to tailor cancer treatments to individual biological characteristics, improving patient outcomes. 2️⃣ Significant disparities in PO infrastructure and access across Europe highlight the need for aligned policies and investments. 📊 Could the uneven distribution of PO resources in Europe hinder the fight against cancer, and what can be done to ensure equitable access? #PrecisionOncology #HealthEquality #FutureOfCancerTreatment For more details, you can read the full article below. https://lnkd.in/d7aDNFFn EFPIA - European Federation of Pharmaceutical Industries and Associations

Virtual sites have the power to transform oncology clinical trials. Science 37 VP of Oncology Dr. Shaalan Beg breaks down what a virtual site is, and how it can deliver better trials for both patients and sponsors in this playbook: https://lnkd.in/eUdCn5P2 #clinicalresearch #clinicaltrials #virtualsite #decentralizedtrials #oncology

Common Sense Oncology will be at this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago! Join us to explore what truly matters to cancer patients, including the balance between science, commercial interests, and the hype around oncology advances. We'll dive into crucial topics such as new drugs, pharmaceutical companies, patient priorities, and the significance of value-based care. Looking forward to insightful discussions with Bishal Gyawali , Queen's University , Tim Hanna Richard Sullivan Susie Stanway,Nazik Hammad,Brian Shkabari,Fidel Rubagumya ,M.D, MMed, MPH, PhD (c) , VERNA VANDERPUYE Dr. Fabio Ynoe de Moraes See you there! #ASCO #Oncology #CancerCare #Science #PatientPriorities #ChicagoMeeting